Product Description
Danaparoid sodium (Orgaran, Organon) is a heparinoid glycosamino-glycuronan antithrombotic agent approved for the prophylaxis of post-operative deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing elective hip replacement surgery. Danaparoid is a low molecular weight heparinoid consisting of a mixture of heparan sulphate (84%), dermatan sulphate (12%) and small amounts of chondroitin sulphate (4%), whose antithrombotic activity has been well established. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11249517/)
Mechanisms of Action: AT III Activator,Factor Xa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | France | Germany | Italy | New Zealand | Portugal | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Aspen Global
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|